Fiera Capital Corp Has $39.05 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Fiera Capital Corp lowered its stake in shares of Danaher Co. (NYSE:DHR) by 4.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 170,117 shares of the conglomerate’s stock after selling 7,781 shares during the period. Fiera Capital Corp’s holdings in Danaher were worth $39,050,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC increased its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its stake in shares of Danaher by 0.6% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock valued at $382,936,000 after purchasing an additional 9,942 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $203.56 on Friday. The firm has a market capitalization of $147.03 billion, a price-to-earnings ratio of 38.55, a PEG ratio of 2.68 and a beta of 0.83. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The business has a fifty day simple moving average of $230.49 and a 200 day simple moving average of $250.28. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the business posted $2.09 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.67 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s payout ratio is 20.45%.

Analyst Upgrades and Downgrades

DHR has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Guggenheim began coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Citigroup lowered their price target on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.